Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 685509 in Hepatic Impairment
NCT03842761Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of avenciguat in Portal Hypertension (PH) and Liver cirrhosis (LC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with drug-related Adverse Events up to 28 days. Started Mar 2019; status: completed.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03842761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842761.